LncRNA CPS1-IT1 serves as anti-oncogenic role in glioma

[Display omitted] •CPS1-IT1 expression is down-regulated in glioma tissues and cells.•Low CPS1-IT1 expression is associated with the malignant status in glioma patients.•Low CPS1-IT1 expression is associated with poor prognosis in glioma patients.•CPS1-IT1 inhibits glioma cell proliferation, migration and invasion. Carbamoyl-phosphate synthetase 1 intronic transcript 1 (CPS1-IT1) is identified recently as a novel tumor suppressive long non-coding RNA (lncRNA). However, the expression status and clinical significance of CPS1-IT1 expression remained unknown in glioma. In our study, we observed CPS1-IT1 levels were decreased in glioma tissues and cells compared with paired normal brain tissues and human astrocyte cell line, respectively. Moreover, we analyzed the associations of CPS1-IT1 expression with clinicopathological characteristics, and found low CPS1-IT1 expression was correlated with high World Health Organisation (WHO) grade and large tumor size in glioma patients. Survival analysis showed glioma patients in low CPS1-IT1 expression group had shorter overall survival than those in high CPS1-IT1 expression group, and low CPS1-IT1 expression was an independent prognostic factor for overall survival in glioma patients. The in vitro studies suggested up-regulation of CPS1-IT1 expression resulted in the decrease of proliferation, migration and invasion abilities of glioma cells. In conclusion, CPS1-IT1 plays an anti-oncogenic role in glioma.